Renal response to angiotensin after short-term angiotensin converting enzyme inhibition. 1993

T Hannedouche, and F Schmitt, and A Ikeni, and L P Marques, and S Natov, and M Déchaux, and B Lacour, and J P Grünfeld
Department of Nephrology, Hôpital Necker, Paris, France.

In 13 normotensive subjects on a normal sodium diet, we studied hormonal, blood pressure, and renal vascular changes and dextran sieving profiles induced by infusion of exogenous angiotensin II (Ang II) (5 ng.kg-1.min-1). during baseline conditions and after 5 days of administration of the angiotensin converting enzyme inhibitor cilazapril. Cilazapril induced a renal vasodilative effect without affecting supine blood pressure and glomerular filtration rate. Fractional dextran clearances were significantly decreased for dextran of effective radius ranging from 3.0 to 4.0 nm. This shift was primarily related to an increase in glomerular capillary plasma flow, because no change was observed in the transcapillary glomerular pressure gradient, the ultrafiltration coefficient, or the membrane parameters. Ang II elicited a slight pressor response accompanied by hormonal, antinatriuretic, and renal hemodynamic changes that were similar during and before short-term angiotensin converting enzyme inhibition. Dextran sieving curves were unchanged by a low dose of Ang II. However, the transcapillary glomerular pressure gradient and the ultrafiltration coefficient were computed to increase by 19.4% and to decrease by 44.2%, respectively, whereas membrane parameters were unaffected. When superimposed onto short-term angiotensin converting enzyme inhibition, glomerular response to this unique dose of Ang II was similar to that induced by Ang II alone. These findings indirectly suggest that most, if not all, of the renal effects of cilazapril are mediated through suppression of Ang II formation.

UI MeSH Term Description Entries
D007668 Kidney Body organ that filters blood for the secretion of URINE and that regulates ion concentrations. Kidneys
D008297 Male Males
D012079 Renal Circulation The circulation of the BLOOD through the vessels of the KIDNEY. Kidney Circulation,Renal Blood Flow,Circulation, Kidney,Circulation, Renal,Blood Flow, Renal,Flow, Renal Blood
D003911 Dextrans A group of glucose polymers made by certain bacteria. Dextrans are used therapeutically as plasma volume expanders and anticoagulants. They are also commonly used in biological experimentation and in industry for a wide variety of purposes. Dextran,Dextran 40,Dextran 40000,Dextran 70,Dextran 75,Dextran 80,Dextran B-1355,Dextran B-1355-S,Dextran B1355,Dextran B512,Dextran Derivatives,Dextran M 70,Dextran T 70,Dextran T-40,Dextran T-500,Hemodex,Hyskon,Infukoll,Macrodex,Polyglucin,Promit,Rheodextran,Rheoisodex,Rheomacrodex,Rheopolyglucin,Rondex,Saviosol,Dextran B 1355,Dextran B 1355 S,Dextran T 40,Dextran T 500
D005260 Female Females
D005919 Glomerular Filtration Rate The volume of water filtered out of plasma through glomerular capillary walls into Bowman's capsules per unit of time. It is considered to be equivalent to INULIN clearance. Filtration Rate, Glomerular,Filtration Rates, Glomerular,Glomerular Filtration Rates,Rate, Glomerular Filtration,Rates, Glomerular Filtration
D006439 Hemodynamics The movement and the forces involved in the movement of the blood through the CARDIOVASCULAR SYSTEM. Hemodynamic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000804 Angiotensin II An octapeptide that is a potent but labile vasoconstrictor. It is produced from angiotensin I after the removal of two amino acids at the C-terminal by ANGIOTENSIN CONVERTING ENZYME. The amino acid in position 5 varies in different species. To block VASOCONSTRICTION and HYPERTENSION effect of angiotensin II, patients are often treated with ACE INHIBITORS or with ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS. Angiotensin II, Ile(5)-,Angiotensin II, Val(5)-,5-L-Isoleucine Angiotensin II,ANG-(1-8)Octapeptide,Angiotensin II, Isoleucine(5)-,Angiotensin II, Valine(5)-,Angiotensin-(1-8) Octapeptide,Isoleucine(5)-Angiotensin,Isoleucyl(5)-Angiotensin II,Valyl(5)-Angiotensin II,5 L Isoleucine Angiotensin II,Angiotensin II, 5-L-Isoleucine

Related Publications

T Hannedouche, and F Schmitt, and A Ikeni, and L P Marques, and S Natov, and M Déchaux, and B Lacour, and J P Grünfeld
April 1982, The American journal of cardiology,
T Hannedouche, and F Schmitt, and A Ikeni, and L P Marques, and S Natov, and M Déchaux, and B Lacour, and J P Grünfeld
December 1997, Kidney international. Supplement,
T Hannedouche, and F Schmitt, and A Ikeni, and L P Marques, and S Natov, and M Déchaux, and B Lacour, and J P Grünfeld
January 1984, Scandinavian journal of urology and nephrology. Supplementum,
T Hannedouche, and F Schmitt, and A Ikeni, and L P Marques, and S Natov, and M Déchaux, and B Lacour, and J P Grünfeld
July 1984, Scandinavian journal of urology and nephrology,
T Hannedouche, and F Schmitt, and A Ikeni, and L P Marques, and S Natov, and M Déchaux, and B Lacour, and J P Grünfeld
November 1981, Kidney international,
T Hannedouche, and F Schmitt, and A Ikeni, and L P Marques, and S Natov, and M Déchaux, and B Lacour, and J P Grünfeld
January 1985, Journal of cardiovascular pharmacology,
T Hannedouche, and F Schmitt, and A Ikeni, and L P Marques, and S Natov, and M Déchaux, and B Lacour, and J P Grünfeld
May 1989, Diabetes research (Edinburgh, Scotland),
T Hannedouche, and F Schmitt, and A Ikeni, and L P Marques, and S Natov, and M Déchaux, and B Lacour, and J P Grünfeld
February 1997, Scandinavian journal of urology and nephrology,
T Hannedouche, and F Schmitt, and A Ikeni, and L P Marques, and S Natov, and M Déchaux, and B Lacour, and J P Grünfeld
May 1990, The American journal of cardiology,
T Hannedouche, and F Schmitt, and A Ikeni, and L P Marques, and S Natov, and M Déchaux, and B Lacour, and J P Grünfeld
January 1992, Journal of cardiovascular pharmacology,
Copied contents to your clipboard!